Plus Therapeutics Awarded $17.6 Million from State of Texas


Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for leptomeningeal metastases.

See the article here:
Plus Therapeutics Awarded $17.6 Million from State of Texas

Related Posts